Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Inhibitor + Progesterone for Fertility Sparing in MMRd Endometrial Cancer
NCT06549855Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Sep 2024
- Primary completion
- Jul 2029
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of sintilimab and pembrolizumab in endometrial cancer (EC), sponsored by Peking University People's Hospital. Primary endpoints: Complete remission rate at 3 months and Time to complete remission at 3 months. Started Sep 2024; status: recruiting.
02
Drugs
sintilimabpembrolizumab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06549855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06549855.